Learn More
Infections contribute significantly to morbidity and mortality after myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). Whether recipients of nonmyeloablative HSCT have(More)
Between 1996 and 2004, a total of 708 patients were enrolled in the acute myeloid leukaemia (AML) ‘96 and ‘02 studies of the East German Study Group (OSHO). Of these, 138 patients (19.5%) had(More)
BACKGROUND Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the treatment of acute myeloid leukaemia. We(More)